Sjögren's disease articles from across Nature Portfolio

In this epidemiological Review, the authors summarize the available evidence relating to the prevalence, incidence, risk factors and mortality associated with the autoimmune disorder Sjögren syndrome, with or without the co-occurrence of other connective tissue diseases.

This Review summarizes the genetic and epigenetic basis of primary Sjögren syndrome, including genetic interactions with factors such as sex and environment. Understanding these processes provides insight into the molecular basis of this disease and might reveal new treatment targets.

No drugs are yet approved for the treatment of primary Sjögren syndrome, despite a large number of clinical trials. Non-conventional approaches can help to identify novel therapeutic targets. Using a drug-repositioning transcriptomic approach, interferon has emerged once again as a major target for intervention in this disease process.

The aryl hydrocarbon receptor (AhR) modulates the function of myeloid-derived suppressor cells (MDSCs) in a mouse model of Sjögren syndrome and is a potential therapeutic target.

By isolating CD4⁺ T cells from patients with primary Sjögren syndrome, a new study has identified the involvement of a targetable interferon signalling pathway in T cell differentiation and B cell activation.

The results of a phase IIb study suggest that ianalumab, an anti-BAFF receptor antibody, could have disease-modifying effects in primary Sjögren syndrome.